Schedule At-A-Glance

Program Book Download Here? Does the info below belong on another page?


Education Program General Overview  

This activity is provided by the American Epilepsy Society. 

 

Accreditation 

The American Epilepsy Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

 

AMA Credit Designation Statement 

The American Epilepsy Society designates this live activity for a maximum of 29.00 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity 

International Credits:  The American Medical Association has determined that non-US Licensed physicians who participate in this CME activity are eligible for AMA PRA Category 1 Credits™. 

Physician Assistants:  AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society.  Physician assistants may receive a maximum of 29.00 hours of Category 1 credit for completing this program. 

Continuing Education for Nurses & Pharmacists 

Continuing Education (CE) credit provided by AKH Inc., Advancing Knowledge in Healthcare 

This activity is eligible for ANCC and ACPE credit.  See final CE activity announcement for specific details. Full accreditation information is available at {website}. 

Credit Claim 

Refer to the {website} for details and instructions about CME and CE credit claiming. 

Annual Meeting Session Types 

The AES Annual Meeting offers high-quality educational programming across diverse work settings, professional roles, and experience levels. Whether you are just starting with the specialty, have a limited background in epilepsy, or are highly fluent with complex topics, you will find sessions and content relevant to your needs. For the most recent program information, visit {website}. 

Symposia — Symposia provide the primary educational activities at the AES Annual Meeting. Topics range from clinically-oriented presentations reviewing common issues in epilepsy to more complex topics combining basic sciences and clinical neurology. While target audiences differ, all symposia include discussion of clinically relevant information. 

Special Interest Groups (SIGs) — SIGs offer information and networking opportunities for attendees with similar interests, in sessions organized by AES members. Although the sizes of SIG sessions vary, all lend themselves to active participation and dialogue. 

Special Lectures — Special lectures recognize the accomplishments of distinguished leaders in clinical epilepsy and research. The Judith Hoyer Lecture in Epilepsy is delivered by an AES President Emeritus. The Lennox and Lombroso Lecture is given by an invited member who has greatly advanced the collective understanding of epilepsy. 

Annual Course — The Annual Course encourages in-depth exploration of important topics related to epilepsy. This session is focused on clinical care; including review of the science underlying featured topics, reviews of clinical research, and discussion of the associated clinical implications. The Annual Course includes a mixture of educational lectures, clinical vignettes, and panel discussions. 

Investigators Workshops — Investigators Workshops highlight exciting developments in basic, translational, and clinical epilepsy research in a format promoting interactive discussion. Speakers include established and junior epilepsy investigators, as well as researchers from other fields. 

Skills Workshops — Skills workshops deliver hands-on and interactive learning opportunities in focused clinical areas or basic science research skills. Attendance at each workshop is limited to a small number of participants to allow optimal interaction. Advanced registration and an additional fee are required. 

Target Audience 

Neurologists, epileptologists, and epilepsy specialist allied health professionals. 

 

DISCLOSURE POLICY 

It is the policy of the American Epilepsy Society to ensure balance, independence, objectivity, and scientific rigor. All individuals involved in the selection, development, and presentation of content are required to disclose any real or apparent conflicts of interest. Conflicts of interest will be resolved by AES prior to an educational activity being delivered to learners.    

RESOLUTION OF CONFLICTS OF INTEREST 

It is the policy of the American Epilepsy Society to ensure balance, independence, objectivity, and scientific rigor. All persons involved in the selection, development, and presentation of content are required to disclose any real or apparent conflicts of interest. In accordance with the ACCME Standards for Commercial Support of CME, AES implemented the mechanisms of prospective peer review of CME activities, to identify and resolve any conflicts. Additionally, the content of these activities is based on the best available evidence. 

UNAPPROVED USE DISCLOSURE 

The American Epilepsy Society requires CME authors to disclose to learners when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the manufacturer’s medical affairs department for the most recent prescribing information. Information about pharmaceutical agents/devices that is outside of U.S. Food and Drug Administration approved labeling may be contained in this activity. 

DISCLAIMER 

This CME activity is for educational purposes only and does not constitute the opinion or endorsement of, or promotion by, the American Epilepsy Society. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information—particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label, investigational and/or experimental uses.